UBS AM
IBRX icon

UBS AM’s ImmunityBio IBRX Stock Holding History

UBS AM’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.66M Sell
531,957
-718
-0.1% -$5.43K ﹤0.01% 1645
2026
Q1 		$4.09M Buy
532,675
+71,499
+16% +$489K ﹤0.01% 1668
2025
Q4 		$913K Buy
461,176
+38,345
+9% +$86.9K ﹤0.01% 2171
2025
Q3 		$1.04M Sell
422,831
-358,969
-46% -$924K ﹤0.01% 1992
2025
Q2 		$2.06M Buy
781,800
+349,459
+81% +$940K ﹤0.01% 2123
2025
Q1 		$1.3M Buy
432,341
+170,607
+65% +$517K ﹤0.01% 2196
2024
Q4 		$670K Sell
261,734
-1,283,068
-83% -$5.35M ﹤0.01% 2500
2024
Q3 		$5.75M Sell
1,544,802
-33,025
-2% -$153K ﹤0.01% 1490
2024
Q2 		$9.97M Buy
1,577,827
+1,394,897
+763% +$9.2M ﹤0.01% 1140
2024
Q1 		$982K Hold
182,930
– – ﹤0.01% 2025
2023
Q4 		$918K Hold
182,930
– – ﹤0.01% 2072
2023
Q3 		$309K Hold
182,930
– – ﹤0.01% 2425
2023
Q2 		$333K Hold
182,930
– – ﹤0.01% 2444
2023
Q1 		$333K Buy
182,930
+35,732
+24% +$111K ﹤0.01% 2444
2022
Q4 		$746K Buy
147,198
+11,843
+9% +$65K ﹤0.01% 2000
2022
Q3 		$673K Sell
135,355
-18,682
-12% -$85.1K ﹤0.01% 2193
2022
Q2 		$573K Buy
154,037
+53,176
+53% +$214K ﹤0.01% 2255
2022
Q1 		$566K Hold
100,861
– – ﹤0.01% 2422
2021
Q4 		$613K Buy
100,861
+57,722
+134% +$434K ﹤0.01% 2464
2021
Q3 		$420K Buy
43,139
+17,217
+66% +$189K ﹤0.01% 2554
2021
Q2 		$370K Buy
25,922
+4,222
+19% +$69.7K ﹤0.01% 2606
2021
Q1 		$515K Buy
21,700
+9,500
+78% +$246K ﹤0.01% 2378
2020
Q4 		$163K Buy
+12,200
New +$117K ﹤0.01% 2524
2016
Q4 		– Sell
-17,700
Closed -$138K – 2565
2016
Q3 		$138K Hold
17,700
– – ﹤0.01% 2530
2016
Q2 		$110K Buy
+17,700
New +$137K ﹤0.01% 2572
2015
Q4 		– Sell
-119,221
Closed -$1.37M – 2705
2015
Q3 		$1.37M Buy
+119,221
New +$2.6M ﹤0.01% 1595

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS AM's IBRX Position: Q2 2026 in Review

UBS AM reduced its ImmunityBio (IBRX) stake by 0.13% in Q2 2026, selling an estimated $5.43K and leaving 531,957 shares worth $4.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1645.

UBS AM first reported a position in IBRX in Q3 2015 and has held it in 26 quarters since. The position peaked at $9.97M in Q2 2024. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • UBS AM held 531,957 shares of ImmunityBio worth $4.66M as of Q2 2026.
  • UBS AM sold 718 ImmunityBio shares in Q2 2026, an estimated $5.43K.
  • ImmunityBio made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1645 holding.
  • UBS AM first reported a position in ImmunityBio in Q3 2015 and has held it in 26 quarters since.
  • UBS AM's ImmunityBio position peaked at $9.97M in Q2 2024.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.